The long‐term incidence of dysplasia and colorectal cancer in a Crohn’s Colitis population‐based cohort

2021 ◽  
Author(s):  
Grace Gatenby ◽  
Tamara Glyn ◽  
John Pearson ◽  
Richard Gearry ◽  
Timothy Eglinton
2021 ◽  
Author(s):  
Milad Fahim ◽  
Lea M. Dijksman ◽  
Thijs A. Burghgraef ◽  
Paul B. van der Nat ◽  
Wouter J.M. Derksen ◽  
...  

2014 ◽  
Vol 46 (4) ◽  
pp. 376-382 ◽  
Author(s):  
Isabelle Fournel ◽  
Vanessa Cottet ◽  
Christine Binquet ◽  
Valérie Jooste ◽  
Jean Faivre ◽  
...  

2020 ◽  
Vol 13 (7) ◽  
pp. 611-622
Author(s):  
Ruth Elisa Eyl ◽  
Lena Koch-Gallenkamp ◽  
Lina Jansen ◽  
Viola Walter ◽  
Prudence R. Carr ◽  
...  

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Ruth Elisa Eyl ◽  
Melissa S. Y. Thong ◽  
Prudence R. Carr ◽  
Lina Jansen ◽  
Lena Koch-Gallenkamp ◽  
...  

2016 ◽  
Vol 32 (8) ◽  
pp. 1367-1374
Author(s):  
Jinma Ren ◽  
Carmen S. Kirkness ◽  
Minchul Kim ◽  
Carl V. Asche ◽  
Srinivas Puli

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 527-527
Author(s):  
Joseph Sung ◽  
Kelvin Kf Tsoi

527 Background: Aspirin, commonly used for prevention of cardiovascular and cerebrovascular diseases, is well-known to protect against colorectal cancer (CRC) development but increase risk of gastrointestinal bleeding (GIB). Few large-scale studies have compared the benefit and risk of long-term aspirin usage. This cohort study aims to evaluate the use of low-dose aspirin to prevent CRC and the risk of GIB associated with the aspirin use. Methods: A population-based clinical dataset was used to compare incidence and mortality of CRC and GIB patients receiving low-dose aspirin with sex-and-age matched controls (in 1:2 ratio). Patients with aspirin≤6 months were excluded. Clinical data of 206,243 aspirin users (mean dose 80 mg/day, mean duration 7.7 years) and 482,966 non-users were included. All patients must have at least 10-year follow up on clinical outcome. Results: Among aspirin users 5,776 (2.80%) were diagnosed with CRC; 2,097 (1.02%) died of the malignancy. 16,483 (3.41%) non-users were diagnosed with CRC; 7,963 (1.65%) died of CRC. Using the cox-proportional hazard regression, aspirin usage showed a modest but significant reduction in CRC mortality (HR = 0.65; 95% CI = 0.62 to 0.69). On the other hand, 11,187 (5.42%) aspirin users developed GIB, and 841 (0.41%) died. 15,186 (3.14%) non-users developed GIB, and 1,682 patients (0.35%) died. Aspirin users showed modest but significant increased risk of GIB-related mortality (HR = 1.24; 95% CI = 1.14 to 1.35). Conclusions: The long-term use of low dose aspirin shows preventive effect on CRC, but also increases the associated GIB risk. Considerations of prophylactic use of aspirin should balance the benefit and the risk of this treatment to the target population. [Table: see text]


Gut ◽  
2011 ◽  
Vol 61 (8) ◽  
pp. 1180-1186 ◽  
Author(s):  
Vanessa Cottet ◽  
Valérie Jooste ◽  
Isabelle Fournel ◽  
Anne-Marie Bouvier ◽  
Jean Faivre ◽  
...  

2011 ◽  
Vol 16 (11) ◽  
pp. 1626-1636 ◽  
Author(s):  
Agnès Caravati‐Jouvenceaux ◽  
Guy Launoy ◽  
Delphine Klein ◽  
Michel Henry‐Amar ◽  
Edwige Abeilard ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document